The shift away from isotopic technologies in favor of their safer, less-expensive non-isotopic counterparts is reshaping this industry. This report from Frost & Sullivan s team of medical industry experts looks at the ramifications of this transition, and discusses what lies ahead for radioimmunoassay market participants. It also offers a glimpse into the promising future of the chemiluminescent segment. Profiles of top companies like Bayer, Hybritech, Ortho, and Dade-Behring are included.
